Monitoring levels of nephrotoxicity of different aminoglycosides during febrile neutropenia caused by nephrotoxic chemotherapy: A single centre study

Journal of B.U.ON.

Volumn 15, Issue 2, 2010, Pages 297-302

  Milovic, Marijana ^a   Popov, I ^a   Jezdic, S ^a   Stojanovic, S ^a   Stankovic, V ^a   Radic, S ^b  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b Institute of Oncology   (Serbia)

Author keywords

Aminoglycosides; Cisplatin; Febrile neutropenia; Nephrotoxicity

Indexed keywords

AMIKACIN; BETA LACTAM ANTIBIOTIC; CISPLATIN; GENTAMICIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; METASTASIS; NEPHROTOXICITY;

ADULT; AMIKACIN; AMINOGLYCOSIDES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; FEMALE; FEVER; GENTAMICINS; HEMATOLOGIC NEOPLASMS; HUMANS; KIDNEY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS; NEUTROPENIA; PROSPECTIVE STUDIES;

EID: 77954407755     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Klastersky J, Paesmans M, Rubenstein EB. The Multinational Association for Supportive Care in Cancer Risk Index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038-3051. (Pubitemid 30644129)
2. Brodersen DE, Clemons WM, Carter AP. Crystal structure of the 30 S ribosomal subunit from Thermus thermophilus: structure of the proteins and their interactions with 16 S RNA. J Mol Biol 2002; 316: 725-768.
3. Carter AP, Clemons WM, Brodersen DE. Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature 2000; 407: 340-348.
4. Hughes WT, Armstrong D, Bodey GP. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751. (Pubitemid 34194843)
5. Foltz F, Ducher M, Rougier F. Efficacy and toxicity of aminoglycoside therapy in the elderly: combined effect of both once-daily regimen and therapeutic drug monitoring. Pathol Biol 2002; 50: 227-232. (Pubitemid 34601686)
6. Jolley ME, Stroupe SD, Wang CH. Fluorescence polarization immunoassay I. Monitoring aminoglycoside antibiotics in serum and plasma. Clin Chem 1981; 27: 1190-1197.
7. Ciarimboli G, Ludwig T, Lang D. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 2005; 167: 1477-1484. (Pubitemid 41713303)
8. Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev 1999; 25: 47-58.
9. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003.
10. Torfoss D, Hoiby EA, Tangen JM et al. Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial. J Antimicrob Chemother 2007; 59: 711-717.
11. Yoshida M, Morita R, Lefor AT et al. Implementation and evaluation of a once-daily amikacin dosing protocol in a long-term care facility. Int J Antimicrob Agents 2007; 29: 113-116. (Pubitemid 44959782)
12. EORTC. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Ann Intern Med 1993; 119: 584-593.
13. Ducher M, Maire P, Cerutti C. Renal elimination of amikacin and aging process. Pharmacokinet 2001; 40: 947-953. (Pubitemid 34066689)
14. Burkhardt O, Lehmann C, Madabusbi R et al. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? J Antimicrob Agents 2007; 29: 113-116.
15. Malacarne P, Bergamasco S, Donadio C et al. Nephrotoxicity due to combination antibiotic therapy with vancomycin and aminoglycosides in septic critically ill patients. Chemotherapy 2006; 52: 178-184. (Pubitemid 43882416)
16. Ferriols-Lisart R, Alos-Alminana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm 1996; 53: 1141-1150. (Pubitemid 26151347)
17. Rossini F, Terrazzi E, Verga L. A randomized clinical trial of ceftriaxone and amikacin versus piperacillin, tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia. Support Care Cancer 2005; 13: 387-392. (Pubitemid 40922357)
18. Parker SE, Davey PG. Once-daily aminoglycoside administration in gram-negative sepsis. Economic and practical aspects. Pharmacoeconomics 1995; 7: 393-402.